CXCR4 高表达在肾细胞癌中的临床病理和预后意义：荟萃分析和文献复习。

Clinicopathological and prognostic significance of CXCR4 high expression in renal cell carcinoma: A meta-analysis and literature review.

机构信息

Department of Radiotherapy, Zhoukou Central Hospital, ZhouKou, 466000, PR China.

出版信息

Int J Surg. 2019 Nov;71:12-18. doi: 10.1016/j.ijsu.2019.08.021. Epub 2019 Sep 5.

DOI:10.1016/j.ijsu.2019.08.021

PMID:31494331

Abstract

INTRODUCTION

Previous results have indicated that CXCR4 is an oncogene in several types of human tumors including renal cell carcinoma (RCC). However, the correlation between CXCR4 expression and clinicopathological characteristics of RCC remains unclear.

MATERIALS AND METHODS

We conducted a meta-analysis to quantitatively evaluate the association of CXCR4 expression with the incidence of RCC and clinicopathological characteristics. Final analysis of 1203 patients with RCC from 14 eligible studies was performed.

RESULTS

We observed that CXCR4 expression is significantly higher in RCC than in normal renal tissue, and the pooled OR from 7 studies including 435 RCC and 297 normal renal tissues was OR = 46.23, 95% CI = 7.18-297.69, p < 0.0001. CXCR4 expression is not associated with gender status and clinical stages. However, CXCR4 expression was significantly associated with pathological grades, metastatic status, and overall survival in patients with RCC.

DISCUSSION

These results indicate that CXCR4 expression is associated with increased risk, progression, and prognosis for patients with RCC. The determination of CXCR4 expression may provide a biomarker for tumor risk evaluation, progression, and prognosis of patients with RCC.

摘要

简介

先前的研究结果表明，趋化因子受体 4（CXCR4）是包括肾细胞癌（RCC）在内的多种人类肿瘤的致癌基因。然而，CXCR4 表达与 RCC 的临床病理特征之间的相关性尚不清楚。

材料与方法

我们进行了一项荟萃分析，以定量评估 CXCR4 表达与 RCC 发生率和临床病理特征的相关性。对来自 14 项合格研究的 1203 例 RCC 患者进行了最终分析。

结果

我们观察到，与正常肾组织相比，RCC 中 CXCR4 的表达明显升高，来自 7 项研究（包括 435 例 RCC 和 297 例正常肾组织）的汇总 OR 为 OR=46.23，95%CI=7.18-297.69，p<0.0001。CXCR4 表达与性别状态和临床分期无关。然而，CXCR4 表达与 RCC 患者的病理分级、转移状态和总生存率显著相关。